About FundaMental Pharma
FundaMental Pharma is a Healthcare company based in Heidelberg (Germany) founded in 2016 by Daniela Mauceri, Thomas Schulze, and Hilmar Bading. Provider of drug development research services for peptides gene therapy, and neurological diseases. FundaMental Pharma has raised $10.32 million across 2 funding rounds from investors including High-Tech Gründerfonds, coparion and BioGeneration Ventures. FundaMental Pharma offers products and services including NMDAR/TRPM4 Interface Inhibitors. Its focus areas include Biopharma Outsourcing and Diversified. Its legal entity is FundaMental Pharma GmbH.
Company details
FundaMental Pharma was founded in 2016 in Heidelberg, Germany, as a provider of drug development and research services. Focus is placed on peptides and gene therapy, particularly for neurological diseases. Operations involve collaborative research efforts in the pharmaceutical sector, with services extending to preclinical studies and therapeutic innovation. The company is co-founded by Daniela Mauceri, Thomas Schulze, and Hilmar Bading, supporting advancements in targeted treatments.
- Headquarters Heidelberg, Germany
- Founders Daniela Mauceri, Thomas Schulze, Hilmar Bading
- SectorsHealthcare
- Website fundamentalpharma.com
- Social LinkedIn
- Legal Name Fundamental Pharma Gmbh
- Total Equity Funding$10.32M (USD)
in 2 rounds
- Latest Funding Round$10.32M (USD), Seed
Nov 2022
- InvestorsHigh-Tech Gründerfonds
& 3 more
Products & Services of FundaMental Pharma
FundaMental Pharma offers a comprehensive portfolio of products and services, including NMDAR/TRPM4 Interface Inhibitors.
Inhibitors that selectively target neurotoxicity in neurodegeneration while preserving brain functions.
Funding Insights of FundaMental Pharma
FundaMental Pharma has successfully raised a total of $10.32M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $10.32 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10.32M
- Total Rounds 2
- Last Round Seed — $10.32M
- Investors Count 4
All 2 funding rounds of FundaMental Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2022 | $10.32M | Seed | – | BioGeneration Ventures, Thuja Capital | |
| Jun 2021 | Seed | – | HTGF | – |
4 investors in total: 4 institutional.
Investors in FundaMental Pharma
FundaMental Pharma has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include High-Tech Gründerfonds, coparion and BioGeneration Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments are made in high-tech startups by HTGF. | htgf.de | Bonn, Germany | ||
Venture capital funding for young German technology companies. | coparion.vc | |||
Life science focused VC firm investing in startups in Europe | biogenerationventures.com | Naarden, Netherlands | ||
Early-stage centric life sciences focused VC firm funding in Netherlands, Belgium and the US | thujacapital.com | Utrecht, Netherlands |
Investor details for FundaMental Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of FundaMental Pharma
6 people are tracked at FundaMental Pharma (6 in leadership).
| Name | Role | Group |
|---|---|---|
Daniela Mauceri | Co-Founder | Leadership |
Thomas Schulze | Co-Founder | Leadership |
Hilmar Bading | Co-Founder | Leadership |
Dirk Beher | CEO | Leadership |
Alexander Straub | Head Of | Leadership |
Thomas Fink | Head Of Finance | Leadership |
Complete people profiles for FundaMental Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of FundaMental Pharma
3 dated milestones of FundaMental Pharma across 6 years, from founding to its latest funding, stage changes and deals.
- Founded FundaMental Pharma is founded.
- Funding First funding round.
- Funding Latest funding round, Seed, of $10.3M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Fundamental Pharma
Complete news archive for FundaMental Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about FundaMental Pharma
FundaMental Pharma was founded in 2016 and raised its 1st funding round 5 years after it was founded.
FundaMental Pharma is headquartered in Heidelberg, Germany. It is registered at Heidelberg, Baden-wurttemberg, Germany.
FundaMental Pharma is a funded company, having raised a total of $10.32M across 2 funding rounds to date.
FundaMental Pharma was founded in 2016 in Heidelberg, Germany, as a provider of drug development and research services. Focus is placed on peptides and gene therapy, particularly for neurological diseases. Operations involve collaborative research efforts in the pharmaceutical sector, with services extending to preclinical studies and therapeutic innovation. The company is co-founded by Daniela Mauceri, Thomas Schulze, and Hilmar Bading, supporting advancements in targeted treatments.
FundaMental Pharma offers NMDAR/TRPM4 Interface Inhibitors.
FundaMental Pharma has 4 investors. Key investors include High-Tech Gründerfonds, coparion, BioGeneration Ventures, and Thuja Capital.
FundaMental Pharma operates through Fundamental Pharma Gmbh.